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PHYPERTENSION
Differential Effects of Antihypertensive
Treatment on Left Ventricular Diastolic Function
An ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Substudy
Robyn J. Tapp, PHD,*† Andrew Sharp, MB, CHB,* Alice V. Stanton, MD, PHD,‡
Eoin O’Brien, PHD,§ Nishi Chaturvedi, MD,* Neil R. Poulter, MD,* Peter S. Sever, MD, PHD,*
Simon A. McG. Thom, MD,* Alun D. Hughes, MD, PHD,* Jamil Mayet, MD,*
on behalf of the ASCOT Investigators
London, United Kingdom; Melbourne, Australia; and Dublin, Ireland
Objectives We hypothesized that an amlodipine-based regimen would have more favorable effects on left ventricular (LV)
diastolic function.
Background Different antihypertensive therapies may vary in their effect on LV diastolic function.
Methods The HACVD (Hypertension Associated Cardiovascular Disease) substudy of ASCOT (Anglo-Scandinavian Cardiac
Outcomes Trial) collected detailed cardiovascular phenotypic data on a subset of 1,006 participants recruited
from 2 centers (St. Mary’s Hospital, London, and Beaumont Hospital, Dublin). Conventional and tissue Doppler
echocardiography and measurement of plasma B-type natriuretic peptide (BNP) were performed approximately
1 year after randomization to atenolol-based or amlodipine-based antihypertensive treatment to assess LV dia-
stolic function.
Results On-treatment blood pressure (BP) (mean SD) was similar in both groups: atenolol-based regimen, systolic BP of
137  17 mm Hg, diastolic BP of 82  9 mm Hg; amlodipine-based regimen, systolic BP of 136 15 mm Hg, dia-
stolic BP of 80  9 mm Hg. Ejection fraction did not differ between groups, but early diastolic mitral annular velocity
(E=), a measure of diastolic relaxation, was lower in patients on the atenolol-based regimen: atenolol-based regimen,
7.9  1.8; amlodipine-based regimen, 8.8 2.0. A measure of left ventricular filling pressure, E/E=, and BNP were
significantly higher in patients on the atenolol-based regimen. Differences in E=, E/E=, and BNP remained significant
after adjustment for age and sex. Further adjustment for systolic BP, LV mass index, and heart rate had no impact on
differences in mean E= or BNP. The difference in E/E= was attenuated.
Conclusions Patients receiving treatment with an amlodipine-based regimen had better diastolic function than patients
treated with the atenolol-based regimen. Treatment-related differences in diastolic function were independent of
BP reduction and other factors that are known to affect diastolic function. (J Am Coll Cardiol 2010;55:
1875–81) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.11.084m
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nd in many patients is related to impaired left ventricular
LV) systolic function. However, heart failure is also com-
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ccepted November 18, 2009.only associated with diastolic dysfunction and apparently
reserved systolic function. This accounts for approximately
ne-third to one-half of heart failure cases (2,3), and most
f these patients have a history of hypertension (1), often
ith LV hypertrophy and remodeling (4–8).
While many studies have focused on the effectiveness of
ypertension treatment in reducing cardiac hypertrophy,
ess is known about the impact of treatment on LV diastolic
unction (8,9). Previous studies addressing the impact of
ifferent antihypertensive agents on LV diastolic function
ave largely used conventional echocardiography assessing
ransmitral filling and isovolumic relaxation. These conven-
ional assessments have limitations as measures of LV
iastolic function are load dependent, which makes it
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loading conditions from intrinsic
changes in LV diastolic function
due to treatment. Second, the
conventional parameters can un-
dergo “pseudonormalization,”
where the ratio of the early to
atrial transmitral peak velocity
(E/A ratio) paradoxically in-
creases with progressive diastolic
impairment. Tissue Doppler
echocardiography (TDE) offers
improved assessment of diastolic
function (10). TDE measure-
ments of myocardial velocities are
significantly less load dependent
than conventional echocardio-
graphic measurements; these mea-
surements do not show pseudo-
normalization and independently
redict cardiovascular events and mortality (11–13). Few stud-
es to date have used TDE to assess diastolic function in
elation to the effects of different antihypertensive agents.
The ASCOT (Anglo-Scandinavian Cardiac Outcomes
rial) study was a large multicenter randomized clinical trial
hat compared the effects of a beta-blocker plus diuretic
atenolol and bendroflumethiazide-K) regimen with a
alcium-antagonist plus angiotensin-converting enzyme
amlodipine and perindopril) regimen on nonfatal myocar-
ial infarction and fatal coronary heart disease (14). The
tudy showed the amlodipine-based regimen was superior to
he atenolol-based regimen on all major cardiovascular end
oints and all-cause mortality. As part of this ASCOT
ubstudy, extensive data on LV diastolic function were
ollected using both conventional echocardiography and
DE. This provides the ideal setting to determine the
mpact of different antihypertension treatment regimens
n LV diastolic function. We hypothesized that the
mlodipine-based regimen would have more favorable
ffects on LV diastolic function in this large group of
ell-controlled hypertensive subjects.
ethods
atients. The population, methods, and response rate for
he ASCOT study are described in detail elsewhere (15). In
rief, the ASCOT study was a clinical trial of blood pressure
BP)-lowering regimens in 19,342 men and women, age 40
o 79 years, with hypertension. Patients eligible for inclusion
ad hypertension and 3 pre-specified cardiovascular risk
actors. Risk factors included male sex, current smoking, age
55 years, microalbuminuria/proteinuria, type 2 diabetes
ellitus, left ventricular hypertrophy (LVH), electrocardio-
raphic abnormalities, a history of early coronary heart
isease in a first-degree relative, ratio of plasma total
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
BP  blood pressure
E=  early diastolic mitral
annular velocity
E/A ratio  early
transmitral peak velocity
E/E=  transmitral E-wave/
E-wave velocity ratio
LV  left ventricular
LVMI  left ventricular
mass index
SBP  systolic blood
pressure
TDE  tissue Doppler
echocardiographyholesterol to high-density lipoprotein cholesterol of 6, meripheral vascular disease, and a history of cerebrovascular
vents. All participants were randomly assigned to either
tenolol  bendroflumethiazide-K (atenolol-based regi-
en) or amlodipine  perindopril (amlodipine-based reg-
men). In addition, patients with a nonfasting cholesterol
evel of 6.5 mmol/l not already receiving lipid-lowering
herapy were randomly assigned to either atorvastatin 10 mg
r placebo. Participants had no history of heart failure,
yocardial infarction, angina, uncontrolled arrhythmias, or
erebrovascular event within the past 3 months. They did
ot have fasting triglycerides4.5 mmol/l or any important
ematological or biochemical abnormality on routine
creening.
Detailed cardiovascular phenotypic data were collected in
he HACVD (Hypertension-Associated Cardiovascular
isease) substudy after approximately 1 year of treatment
rom a subset of 1,006 participants recruited from 2 centers
St. Mary’s Hospital, London, and the Adapt Center,
eaumont Hospital, Dublin). Echocardiography was per-
ormed using an ATL HDI 5000 ultrasound machine
quipped with a standard multifrequency transducer 12
onths after initiation of treatment. All scans were per-
ormed by 3 experienced echocardiographers with the pa-
ient semirecumbent in the left lateral position. Interob-
erver reproducibility data were acquired and showed
ariations for all echocardiographic parameters between
.5% and 7.5%. This is within acceptable limits as per
revious studies (16). The LV measurements were per-
ormed using M-mode from the parasternal long-axis view
ccording to the American Society of Echocardiography
onventions (17), and LV mass was calculated according to
he formula:
LV mass
0.8 [(IVSdLVIDdPWTd)3 (LVIDd)3] 0.6 g
here IVSd  intraventricular septal thickness in diastole,
VIDd  left ventricular diameter in diastole, and PWTd
posterior wall thickness in diastole. This was then
ndexed for body surface area to give the left ventricular
ass index (LVMI). Ejection fraction was calculated using
he Teicholz formula from the parasternal long-axis view
sing M-mode, or if not technically possible, Simpson’s rule
as used.
Transmitral Doppler was assessed using a 5-mm sample
olume placed at the tips of the mitral leaflets in passive
nd-expiration. A standardized loop of 10 cardiac cycles was
ownloaded to computer for off-line analysis of the early
lling phase (E-wave) and the late filling phase (A-wave).
he TDE was performed in the apical 4-, 2-, and
-chamber views, with the 5-mm sample volume placed
ver the myocardium on the septal, lateral, and inferior walls
t the level of the mitral annulus and the free wall of the
ight ventricle at the level of the tricuspid annulus. Using
inimal gain settings, a series of 10 cardiac cycles were
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April 27, 2010:1875–81 Antihypertensive Treatment and Diastolic Functionecorded. These were then downloaded for off-line anal-
sis, with measurements made of systolic velocity (S=-
ave), early diastolic velocity (E=-wave), and late dia-
tolic velocity (A=-wave) at each location, and these were
veraged. Analysis was performed using the HDI Lab-
ratory software (Philips, Surrey, United Kingdom) by a
ingle researcher who was blinded to all patient details.
ach value represents the mean of 3 measurements taken
rom 3 consecutive representative cardiac cycles.
Blood pressure was measured after resting in a seated
osition for 5 min, using an Omron HEM 705-CP semiau-
omatic oscillometric recorder (Philips). Height and weight
ere measured in light clothing by a trained observer. Body
ass index was calculated as weight (kg)/height (m2). Infor-
ation on history of diabetes was obtained by interview.
lasma glucose and serum total cholesterol were measured
sing standard enzymatic methods on a Roche/Hitachi 921
Roche Diagnostics, Basel, Switzerland) automated analyzer.
B-type natriuretic peptide (BNP) was analyzed with the
ayer BNP assay (Bayer Diagnostics, Newbury, Great
ritain) with standard quality control methods. Results
uoted are in pg/ml. The ADVIA Centaur BNP assay
Bayer Diagnostics) is a fully automated 2-site sandwich
mmunoassay using 2 monoclonal antibodies, which mea-
ures only the physiologically active BNP (77-108) mole-
ule. The assay has been well validated (18).
The study conformed to good clinical practice guidelines
nd was approved by the respective local hospital ethics
ommittees (St. Mary’s Hospital, London, and Beaumont
ospital, Dublin). Written informed consent for the study
as obtained from all participants.
tatistical methods. Data analysis was performed with
PSS version 15.0.0 for Windows (SPSS Inc., Chicago,
llinois). Descriptive information for each of the variables
as obtained and distributions assessed. The BNP and
Characteristics of the Population at BaselineTable 1 Characteristics of the Population at
Atenolol-B
(n
Eligibility risk factors
Age 55 yrs 349
Male 332
Peripheral arterial disease 25
Prior known ECG or echocardiogram LVH 16
Diabetes mellitus 82
Smoker 85
Baseline characteristics
Age, yrs 62
Systolic blood pressure, mm Hg 159
Diastolic blood pressure, mm Hg 92
Heart rate, beats/min 71
Body surface area, m2 2
BMI, kg/m2 28
Total cholesterol, mmol/l 5
Triglycerides, mmol/l* 1.6Values are n (%) or mean  SD. *Data are median and interquartile range.
BMI  body mass index; ECG  electrocardiogram; LVH  left ventricularriglycerides values were skewed and were therefore log-
ransformed to permit subsequent parametric analysis. Data
re presented as mean (SD), or median (interquartile range)
or skewed data), and percentages. Statistical comparisons
ere made using a Student t test (or a Mann-Whitney U
est as appropriate) for metric variables and a chi-square test
or categorical variables. Multivariate analysis of variance
as also used to assess the difference between treatments
ith covariate adjustment; because BNP data were skewed,
hey were log-transformed before multivariate analysis to
ermit subsequent parametric analysis. Geometric mean 
tandard error are quoted for BNP. All p values 0.05 were
onsidered statistically significant.
esults
aseline demographic and clinical characteristics of the 2
reatment groups were similar (Table 1). After 12 months of
reatment, systolic BP was reduced to a similar extent by
oth treatment regimens (Table 2), but, predictably, heart
ate was significantly lower in the atenolol-based regimen.
jection fraction did not differ between groups. The LVMI
ended to be lower in patients treated with the amlodipine-
ased regimen, although this did not achieve statistical
ignificance (p  0.089). Treatment with the amlodipine-
ased regimen was associated with higher early diastolic
itral annular velocity (E=), lower plasma BNP, lower
/E=, a smaller atrial diameter, and a shorter E-wave
eceleration time, whereas E/A ratio was higher in people
andomly assigned to the atenolol-based regimen (Table 2).
After adjustment for age and sex, E= remained signifi-
antly lower in patients treated with the atenolol-based
egimen compared to patients randomly allocated to the
mlodipine-based regimen (p  0.001 adjusted for age and
ex) (Table 3), and the intergroup difference remained
eline
Regimen
1)
Amlodipine-Based Regimen
(n  413) p Value
349 (85) 0.870
325 (79) 0.456
25 (6) 0.986
13 (3) 0.557
90 (22) 0.516
99 (24) 0.257
.9 62.4 7.8 0.542
7.5 159.9 18.7 0.965
.7 92.3 9.6 0.349
2.0 70.9 12.5 0.766
.2 1.9 0.2 0.720
.5 28.8 4.6 0.971
.0 5.8 1.0 0.932
.1) 1.5 (1.1–2.1) 0.714Bas
ased
 41
(85)
(81)
(6)
(4)
(20)
(21)
.1 7
.9 1
.9 9
.1 1
.0 0
.2 4
.8 1
(1.1–2hypertrophy.
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Antihypertensive Treatment and Diastolic Function April 27, 2010:1875–81ighly significant (p  0.001) after further adjustment for
ystolic BP and LVMI. Further adjustment for heart rate, a
actor directly related to hypertension treatment, had no
mpact on difference in E= (p  0.001). Differences in E/E=
nd E/A ratio remained significant after adjustment for age,
ex, systolic BP, and LVMI (Table 3). Further adjustment
or heart rate attenuated the difference in E/E= and E/A
etween the treatment regimens (p  0.703 and p  0.139,
espectively). Similar associations were observed for BNP
omparing the treatment regimens (Table 3). No significant
ifferences in LVMI between treatment groups were ob-
erved in unadjusted or adjusted data (Table 3).
iscussion
his is one of the first large randomized clinical trials to
ompare the effect of antihypertensive medications on LV
iastolic function assessed using TDE. In the present
tudy, after approximately 12 months of intensive ther-
py, patients treated with the amlodipine-based regimen
ad evidence of better LV diastolic function compared
ith patients treated with the atenolol-based regimen
i.e., higher E=, lower plasma BNP, lower E/E=, smaller
Characteristics of the Population at Year 1Table 2 Characteristics of the Population at
Atenolol-B
(n
Blood pressure and heart rate
Systolic blood pressure, mm Hg 137
Diastolic blood pressure, mm Hg 81
Heart rate, beats/min 57
2nd-line antihypertensive, %
Cardiac structural and functional measures
LV structural measures
Interventricular septum, diastole, cm 1.2
LV internal dimension, diastole, cm 4.9
Posterior wall thickness, diastole, cm 1.1
Interventricular septum, systole, cm 1.6
LV internal dimension, systole, cm 3.2
Posterior wall thickness, systole, cm 1.5
LV ejection fraction, % 69.4
LVMI, g/m2 122.6
Relative wall thickness 0.5
Left atrial size, cm* 4.2
Transmitral Doppler
E wave, cm/s 60.0
A wave, cm/s 68.2
E/A ratio 0.9
E-wave deceleration time, ms 0.2
Tissue Doppler
Systolic velocity (S=), cm/s 8
Early diastolic velocity (E=), cm/s 7.9
Late diastolic velocity (A=), cm/s 10.7
Mean E/E= ratio 8.1
BNP, pg/ml† 37
Values aremean SD unless otherwise indicated. *Data available for o
BNP  B-type natriuretic peptide; LV  left ventricular; LVMI  lefttrial diameter, and shorter E-wave deceleration time). chese effects were independent of other factors associ-
ted with diastolic dysfunction including the BP-
owering effect of the drug and LVMI. Differences in
/E= between the 2 treatment regimens could be ac-
ounted for by differences in heart rate, but this did not
xplain the differences in E= or BNP. The difference in
/A ratio, a widely used indicator of diastolic function,
as discordant with other more sensitive measures of
iastolic function, in that unadjusted E/A was higher in
he atenolol-based regimen. This difference was also
ccounted for by differences in heart rate. A previous
tudy also observed an improvement in the E/A ratio
fter 48 weeks of treatment with atenolol, which was
ighly correlated with the reduction in heart rate (8). We,
herefore, suggest that E/A ratio is not a particularly
seful indicator of diastolic function when heart rate
iffers between treatments. Differences in diastolic func-
ion seen in this study could be a consequence of
ifferences in mechanisms of action of the drugs: amlo-
ipine, perindopril, and bendroflumethiazide reduce
lood pressure principally by reducing peripheral resis-
ance, whereas atenolol has negative cardiac inotropic and
r 1
Regimen
1)
Amlodipine-Based Regimen
(n  413) p Value
7.4 136.2 14.6 0.167
.3 80.1 8.6 0.012
0.0 72.8 11.4 0.001
43 0.386
.23 1.26 0.23 0.170
.55 4.84 0.60 0.046
.18 1.18 0.18 0.761
.25 1.63 0.27 0.352
.55 3.22 0.56 0.180
.25 1.59 0.23 0.510
1.32 69.21 12.19 0.759
0.92 118.80 31.56 0.089
.10 0.51 0.10 0.412
.59 4.14 0.64 0.022
4.87 63.41 15.01 0.001
4.63 75.08 15.76 0.001
.29 0.86 0.22 0.004
.05 0.18 0.05 0.001
.75 9.5 2.21 0.001
.84 8.76 2.04 0.001
.15 12.34 2.31 0.001
.38 7.76 2.05 0.013
6) 19 (10–34) 0.001
patients for left atrial size. †Data aremedian and interquartile range.
ular mass index.Yea
ased
 41
.8 1
.6 9
.8 1
40
7 0
2 0
7 0
5 0
7 0
8 0
8 1
6 3
1 0
5 0
8 1
5 1
1 0
0 0
.2 1
1 1
6 2
4 2
(20–5hronotropic effects (19).
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April 27, 2010:1875–81 Antihypertensive Treatment and Diastolic FunctionAmong patients 65 years of age and more with evidence
f diastolic dysfunction, approximately 15% will have heart
ailure within 5 years (20). Effective treatment could poten-
ially delay or reduce the number of people having LV
iastolic dysfunction and later progression to heart failure.
revious research has suggested that antihypertensive med-
cations vary in their ability to maintain or improve LV
iastolic function and filling pressure (8,21,22). In particu-
ar, many studies have focused on effectiveness of hyperten-
ion treatments on LV mass; however, because of serious
imitations of the study designs and methodologies, conclu-
ions from these studies have been viewed with great caution
23). In general, studies have used small samples sizes
8,21,24–26) and have been underpowered to detect a
ifference between therapies. The majority of study dura-
ions have ranged from just a few weeks to 6 months
21,25,26), and very few studies have extended to a year of
ollow-up (8,24,27). Moreover, conventional echocardiog-
aphy alone, which has been used in the majority of
ublished studies, has limitations as a means of assessing LV
iastolic function (28,29).
As far as we are aware, no previous large randomized
linical trials have evaluated the effect of antihypertensive
reatment on LV diastolic function using TDE. Two small
tudies that have used TDE to compare the effectiveness of
ntihypertensive treatments on LV diastolic function have
ielded conflicting results (8,30). In a recent study of 134
Multivariate Analysis, Echocardiographic MeasuTable 3 Multivariate Analysis, Echocardiogr
Atenol
Left ventricular mass index
Model 1 adjusted for age and sex 1
Model 2 adjusted for model 1 and SBP 1
Model 3 adjusted for model 1, SBP, HR 1
E/A ratio
Model 1 adjusted for age and sex
Model 2 adjusted for model 1 and LVMI
Model 3 adjusted for model 1 and SBP
Model 4 adjusted for model 1, LVMI, SBP, HR
Mean early diastolic velocity (E=) cm/s
Model 1 adjusted for age and sex
Model 2 adjusted for model 1 and LVMI
Model 3 adjusted for model 1 and SBP
Model 4 adjusted for model 1, LVMI, SBP, HR
Mean E/E= ratio
Model 1 adjusted for age and sex
Model 2 adjusted for model 1 and LVMI
Model 3 adjusted for model 1 and SBP
Model 4 adjusted for model 1, LVMI, SBP, HR
BNP pg/ml
Model 1 adjusted for age and sex
Model 2 adjusted for model 1 and LVMI
Model 3 adjusted for model 1 and SBP
Model 4 adjusted for model 1, LVMI, SBP, HR
All values are mean  standard error; BNP data were log transformed
HR  heart rate; SBP  systolic blood pressure; other abbreviationubjects, irbesartan, an angiotensin AT1-receptor blocker, (roduced greater improvement in E/E= compared with
tenolol among subjects with and without hypertensive LV
ypertrophy (8). In contrast, in a study of 186 subjects with
vidence of diastolic dysfunction, valsartan, an AT1-
eceptor blocker, was shown to be no more effective than
tandard treatment in improving LV diastolic function over
8 weeks (30). Our findings, based on a large number of
articipants, demonstrate clear benefits in terms of diastolic
unction in those randomized to the amlodipine-based
egimen compared with those randomized to the atenolol-
ased regimen. This finding is of interest since TDE
easures of diastolic function have been reported to predict
ardiovascular events and mortality (11,12). Similarly, al-
hough the BNP values were largely within the normal
ange, data from the Framingham study indicate a signifi-
antly increased cardiovascular event rate is associated with
mall increases in BNP levels, even at levels thought to be
ithin the normal range (31).
tudy limitations. The majority of participants were male,
lderly, and of white European ethnicity, and so our
bservations may not necessarily be extrapolated to other
ypertensive patients. Additionally, patients were required
o have at least 3 other cardiovascular disease risk factors;
owever, these included age 55 years and male sex.
verall in the ASCOT study, the total primary event rate
i.e., nonfatal myocardial infarction, including silent, plus
atal coronary heart disease) was 8.5 per 1,000 patient years
y Treatment GroupMeasures by Treatment Group
ed Regimen Amlodipine-Based Regimen p Value
 1.81 117.25 1.80 0.096
 1.78 116.77 1.80 0.155
 1.92 118.67 1.94 0.879
 0.02 0.85 0.02 0.007
 0.02 0.85 0.02 0.004
 0.02 0.85 0.02 0.004
 0.02 0.90 0.02 0.139
 0.11 8.59 0.10 0.001
 0.11 8.54 0.11 0.001
 0.11 8.62 0.11 0.001
 0.12 8.64 0.12 0.001
 0.13 8.00 0.13 0.043
 0.13 8.03 0.13 0.060
 0.13 8.00 0.13 0.031
 0.14 8.12 0.14 0.703
 1.05 19.26 1.05 0.001
 1.05 19.57 1.05 0.001
 1.05 19.36 1.05 0.001
 1.05 22.02 1.05 0.001
e in multivariate analysis of variance.
Table 2.res baphic
ol-Bas
21.02
19.92
18.26
0.90
0.90
0.91
0.87
7.76
7.78
7.80
7.72
8.32
8.32
8.31
8.20
35.80
35.69
35.87
32.5214), so the participants should not be regarded as a
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Antihypertensive Treatment and Diastolic Function April 27, 2010:1875–81articularly high risk group. Measures of LV diastolic
unction were not recorded at baseline, and therefore we
annot comment on how treatment changed diastolic func-
ion from the pre-treatment state. However, this limitation
oes not extend to the comparison of treatment regimens,
ecause randomization is likely to balance time effects of
nmeasured covariates (32). Finally, approximately 40%
f participants in both treatment groups received 2
ntihypertensive agent as part of the treatment regimen,
o differences cannot be attributed to any individual drug
n each regimen.
onclusions
his prospective randomized study in hypertensive patients
howed that those receiving treatment with the amlodipine-
ased regimen have better diastolic function than those
reated with the atenolol-based regimen. Treatment-related
ifferences in diastolic function were independent of BP
eduction and other factors that are known to affect diastolic
unction.
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